ArticleTherapeutic advances in hematology2024

Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.

Yingling Zu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.